Non-alcoholic Fatty Liver Disease (NAFLD) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2034
The 7 major Non-alcoholic fatty liver disease (NAFLD) markets reached a value of US$ 13.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 18.4 Million by 2034, exhibiting a growth rate (CAGR) of 3.2% during 2024-2034.
The Non-alcoholic fatty liver disease (NAFLD) market has been comprehensively analyzed in IMARC’s new report titled “Non-alcoholic fatty liver disease (NAFLD) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast”. Non-alcoholic fatty liver disease refers to a medical ailment that is distinguished by an excess of fat deposited in liver cells. This disease can be primarily categorized into non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). Indiviuals suffering with non-alcoholic fatty liver disease can develop non-alcoholic steatohepatitis, which may further lead to severe scarring (cirrhosis) and liver failure. Non-alcoholic fatty liver disease include some of the common symptoms, such as liver malfunction, pain in the upper right side of the abdomen, fluid and swelling in the stomach (ascites) and legs (edema), malaise, weariness, a dull right-upper-quadrant abdominal discomfort, loss of weight, etc. In some cases, where non-alcoholic fatty liver disease shows no symptoms, it seldom comes to medical attention until tests are performed for other reasons that indicate a liver condition. As a result, this indication necessitates a specific sort of test to be diagnosed. A liver ultrasound scan or magnetic resonance imaging (MRI) can be used to identify metabolic derangements. A liver biopsy is then performed to aid in the diagnosis and differentiation of both kinds of NAFLD (including NAFL and NASH) from other types of liver disease. These specific diagnostics are followed by blood tests, which also contribute to validating the diagnosis.
The increasing prevalence of diabetes and obesity owing to the changing dietary patterns and sedentary lifestyles of the consumers is primarily driving the global non-alcoholic fatty liver disease market. In addition to this, the sudden outbreak of the coronavirus infection has also led to a high risk of hepatic damage and liver-related fatalities, particularly among cirrhotic individuals. This, in turn, is further acting as a significant growth-inducing factor. Moreover, several technological advancements related to genetic testing for early and effective disease diagnosis are also propelling the market growth. Multiple gene mutations are associated with the development of both forms of non-alcoholic fatty liver disease, including NAFL and NASH. Apart from this, the governing agencies of numerous countries, along with non-governmental organizations (NGOs), are supporting various health education campaigns to generate awareness about the risk factors of liver-related disorders, such as non-alcoholic fatty liver disease. Additionally, the introduction of innovative imaging modalities for assessing fatty liver and fibrosis, such as magnetic resonance imaging derived proton density fat fraction and MR elastography, is expected to drive the global non-alcoholic fatty liver disease market in the coming years.
IMARC Group’s new report " Non-alcoholic fatty liver disease (NAFLD) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast" provides an exhaustive analysis of the Non-alcoholic fatty liver disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The report provides an in-depth understanding of current and future landscape of the Non-alcoholic fatty liver disease market. This includes treatment practices, in-market and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Non-alcoholic fatty liver disease across the seven major markets. According to the report the United States has the largest patient pool for Non-alcoholic fatty liver disease and also represents the largest market for Non-alcoholic fatty liver disease treatment. Furthermore, the current Non-alcoholic fatty liver disease treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Non-alcoholic fatty liver disease market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, Current and Future Epidemiology Scenario
Historical, Current and Future Performance of the Non-alcoholic fatty liver disease market
Historical, Current and Future Performance of Various Therapeutic Categories in the Non-alcoholic fatty liver disease market
Sales of Various Drugs Across the Non-alcoholic fatty liver disease market
Reimbursement Scenario in the Non-alcoholic fatty liver disease market
In-Market and Pipeline Drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Non-alcoholic fatty liver disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Non-alcoholic fatty liver disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to be in 2034?
What was the country-wise size of the Non-alcoholic fatty liver disease market across the seven major markets in 2023 and how will it look like in 2034?
What is the growth rate of the Non-alcoholic fatty liver disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the Non-alcoholic fatty liver disease market?
Epidemiology Insights
What is the size of the Non-alcoholic fatty liver disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) of Non-alcoholic fatty liver disease across the seven major markets?
What are the key factors driving the epidemiological trend of Graft-vs Host Disease?
What will be the growth rate of Non-alcoholic fatty liver disease patients across the seven major markets?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed Non-alcoholic fatty liver disease drugs and what are their market performance?
What are the key pipeline Non-alcoholic fatty liver disease drugs and how are they expected to perform in the coming years?
How safe are the current marketed Non-alcoholic fatty liver disease drugs and what are their efficacies?
How safe are the late-stage pipeline Non-alcoholic fatty liver disease drugs and what are their efficacies?
What are the current treatment guidelines for Non-alcoholic fatty liver disease drugs across the seven major markets?
Who are the key companies in the Non-alcoholic fatty liver disease market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Non-alcoholic fatty liver disease market?
The Non-alcoholic fatty liver disease (NAFLD) market has been comprehensively analyzed in IMARC’s new report titled “Non-alcoholic fatty liver disease (NAFLD) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast”. Non-alcoholic fatty liver disease refers to a medical ailment that is distinguished by an excess of fat deposited in liver cells. This disease can be primarily categorized into non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). Indiviuals suffering with non-alcoholic fatty liver disease can develop non-alcoholic steatohepatitis, which may further lead to severe scarring (cirrhosis) and liver failure. Non-alcoholic fatty liver disease include some of the common symptoms, such as liver malfunction, pain in the upper right side of the abdomen, fluid and swelling in the stomach (ascites) and legs (edema), malaise, weariness, a dull right-upper-quadrant abdominal discomfort, loss of weight, etc. In some cases, where non-alcoholic fatty liver disease shows no symptoms, it seldom comes to medical attention until tests are performed for other reasons that indicate a liver condition. As a result, this indication necessitates a specific sort of test to be diagnosed. A liver ultrasound scan or magnetic resonance imaging (MRI) can be used to identify metabolic derangements. A liver biopsy is then performed to aid in the diagnosis and differentiation of both kinds of NAFLD (including NAFL and NASH) from other types of liver disease. These specific diagnostics are followed by blood tests, which also contribute to validating the diagnosis.
The increasing prevalence of diabetes and obesity owing to the changing dietary patterns and sedentary lifestyles of the consumers is primarily driving the global non-alcoholic fatty liver disease market. In addition to this, the sudden outbreak of the coronavirus infection has also led to a high risk of hepatic damage and liver-related fatalities, particularly among cirrhotic individuals. This, in turn, is further acting as a significant growth-inducing factor. Moreover, several technological advancements related to genetic testing for early and effective disease diagnosis are also propelling the market growth. Multiple gene mutations are associated with the development of both forms of non-alcoholic fatty liver disease, including NAFL and NASH. Apart from this, the governing agencies of numerous countries, along with non-governmental organizations (NGOs), are supporting various health education campaigns to generate awareness about the risk factors of liver-related disorders, such as non-alcoholic fatty liver disease. Additionally, the introduction of innovative imaging modalities for assessing fatty liver and fibrosis, such as magnetic resonance imaging derived proton density fat fraction and MR elastography, is expected to drive the global non-alcoholic fatty liver disease market in the coming years.
IMARC Group’s new report " Non-alcoholic fatty liver disease (NAFLD) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast" provides an exhaustive analysis of the Non-alcoholic fatty liver disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The report provides an in-depth understanding of current and future landscape of the Non-alcoholic fatty liver disease market. This includes treatment practices, in-market and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Non-alcoholic fatty liver disease across the seven major markets. According to the report the United States has the largest patient pool for Non-alcoholic fatty liver disease and also represents the largest market for Non-alcoholic fatty liver disease treatment. Furthermore, the current Non-alcoholic fatty liver disease treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Non-alcoholic fatty liver disease market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, Current and Future Epidemiology Scenario
Historical, Current and Future Performance of the Non-alcoholic fatty liver disease market
Historical, Current and Future Performance of Various Therapeutic Categories in the Non-alcoholic fatty liver disease market
Sales of Various Drugs Across the Non-alcoholic fatty liver disease market
Reimbursement Scenario in the Non-alcoholic fatty liver disease market
In-Market and Pipeline Drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Non-alcoholic fatty liver disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Non-alcoholic fatty liver disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to be in 2034?
What was the country-wise size of the Non-alcoholic fatty liver disease market across the seven major markets in 2023 and how will it look like in 2034?
What is the growth rate of the Non-alcoholic fatty liver disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the Non-alcoholic fatty liver disease market?
Epidemiology Insights
What is the size of the Non-alcoholic fatty liver disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) of Non-alcoholic fatty liver disease across the seven major markets?
What are the key factors driving the epidemiological trend of Graft-vs Host Disease?
What will be the growth rate of Non-alcoholic fatty liver disease patients across the seven major markets?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed Non-alcoholic fatty liver disease drugs and what are their market performance?
What are the key pipeline Non-alcoholic fatty liver disease drugs and how are they expected to perform in the coming years?
How safe are the current marketed Non-alcoholic fatty liver disease drugs and what are their efficacies?
How safe are the late-stage pipeline Non-alcoholic fatty liver disease drugs and what are their efficacies?
What are the current treatment guidelines for Non-alcoholic fatty liver disease drugs across the seven major markets?
Who are the key companies in the Non-alcoholic fatty liver disease market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Non-alcoholic fatty liver disease market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 NON-ALCOHOLIC FATTY LIVER DISEASE- INTRODUCTION
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (2024-2034)
4.3 Market Overview (2018-2023) and Forecast (2024-2034)
4.4 Competitive Intelligence
5 NON-ALCOHOLIC FATTY LIVER DISEASE- DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 NON-ALCOHOLIC FATTY LIVER DISEASE- EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
8 NON-ALCOHOLIC FATTY LIVER DISEASE- TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Non-alcoholic Fatty Liver Disease Guidelines, Management and Treatment
8.2 Non-alcoholic Fatty Liver Disease Treatment Algorithm
9 NON-ALCOHOLIC FATTY LIVER DISEASE- UNMET NEEDS
10 NON-ALCOHOLIC FATTY LIVER DISEASE- KEY ENDPOINTS OF TREATMENT
11 NON-ALCOHOLIC FATTY LIVER DISEASE- MARKETED PRODUCTS
11.1 List of Non-alcoholic Fatty Liver Disease Drugs (Off-Label/Marketed) Across the Top 7 Markets
11.1.1 Drug Name - Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 NON-ALCOHOLIC FATTY LIVER DISEASE- PIPELINE DRUGS
12.1 List of Non-alcoholic Fatty Liver Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 Oltipraz - PharmaKing
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Cotadutide - AstraZeneca
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Lanifibranor - Inventiva Pharma
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Pemafibrate - Kowa Pharmaceutical
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Clesacostat - Pfizer
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report.
13. NON-ALCOHOLIC FATTY LIVER DISEASE- ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 NON-ALCOHOLIC FATTY LIVER DISEASE- MARKET SCENARIO
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Non-alcoholic Fatty Liver Disease- Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (2024-2034)
14.2.2 Non-alcoholic Fatty Liver Disease- Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (2024-2034)
14.3 Market Scenario - United States
14.3.1 Non-alcoholic Fatty Liver Disease- Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (2024-2034)
14.3.2 Non-alcoholic Fatty Liver Disease- Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (2024-2034)
14.3.3 Non-alcoholic Fatty Liver Disease- Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Non-alcoholic Fatty Liver Disease- Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (2024-2034)
14.4.2 Non-alcoholic Fatty Liver Disease- Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (2024-2034)
14.4.3 Non-alcoholic Fatty Liver Disease- Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Non-alcoholic Fatty Liver Disease- Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (2024-2034)
14.5.2 Non-alcoholic Fatty Liver Disease- Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (2024-2034)
14.5.3 Non-alcoholic Fatty Liver Disease- Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Non-alcoholic Fatty Liver Disease- Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (2024-2034)
14.6.2 Non-alcoholic Fatty Liver Disease- Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (2024-2034)
14.6.3 Non-alcoholic Fatty Liver Disease- Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Non-alcoholic Fatty Liver Disease- Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (2024-2034)
14.7.2 Non-alcoholic Fatty Liver Disease- Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (2024-2034)
14.7.3 Non-alcoholic Fatty Liver Disease- Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Non-alcoholic Fatty Liver Disease- Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (2024-2034)
14.8.2 Non-alcoholic Fatty Liver Disease- Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (2024-2034)
14.8.3 Non-alcoholic Fatty Liver Disease- Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Non-alcoholic Fatty Liver Disease- Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (2024-2034)
14.9.2 Non-alcoholic Fatty Liver Disease- Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (2024-2034)
14.9.3 Non-alcoholic Fatty Liver Disease- Access and Reimbursement Overview
15 NON-ALCOHOLIC FATTY LIVER DISEASE- RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
16 NON-ALCOHOLIC FATTY LIVER DISEASE MARKET - SWOT ANALYSIS
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 NON-ALCOHOLIC FATTY LIVER DISEASE- INTRODUCTION
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (2024-2034)
4.3 Market Overview (2018-2023) and Forecast (2024-2034)
4.4 Competitive Intelligence
5 NON-ALCOHOLIC FATTY LIVER DISEASE- DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 NON-ALCOHOLIC FATTY LIVER DISEASE- EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
8 NON-ALCOHOLIC FATTY LIVER DISEASE- TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Non-alcoholic Fatty Liver Disease Guidelines, Management and Treatment
8.2 Non-alcoholic Fatty Liver Disease Treatment Algorithm
9 NON-ALCOHOLIC FATTY LIVER DISEASE- UNMET NEEDS
10 NON-ALCOHOLIC FATTY LIVER DISEASE- KEY ENDPOINTS OF TREATMENT
11 NON-ALCOHOLIC FATTY LIVER DISEASE- MARKETED PRODUCTS
11.1 List of Non-alcoholic Fatty Liver Disease Drugs (Off-Label/Marketed) Across the Top 7 Markets
11.1.1 Drug Name - Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 NON-ALCOHOLIC FATTY LIVER DISEASE- PIPELINE DRUGS
12.1 List of Non-alcoholic Fatty Liver Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 Oltipraz - PharmaKing
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Cotadutide - AstraZeneca
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Lanifibranor - Inventiva Pharma
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Pemafibrate - Kowa Pharmaceutical
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Clesacostat - Pfizer
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report.
13. NON-ALCOHOLIC FATTY LIVER DISEASE- ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 NON-ALCOHOLIC FATTY LIVER DISEASE- MARKET SCENARIO
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Non-alcoholic Fatty Liver Disease- Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (2024-2034)
14.2.2 Non-alcoholic Fatty Liver Disease- Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (2024-2034)
14.3 Market Scenario - United States
14.3.1 Non-alcoholic Fatty Liver Disease- Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (2024-2034)
14.3.2 Non-alcoholic Fatty Liver Disease- Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (2024-2034)
14.3.3 Non-alcoholic Fatty Liver Disease- Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Non-alcoholic Fatty Liver Disease- Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (2024-2034)
14.4.2 Non-alcoholic Fatty Liver Disease- Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (2024-2034)
14.4.3 Non-alcoholic Fatty Liver Disease- Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Non-alcoholic Fatty Liver Disease- Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (2024-2034)
14.5.2 Non-alcoholic Fatty Liver Disease- Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (2024-2034)
14.5.3 Non-alcoholic Fatty Liver Disease- Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Non-alcoholic Fatty Liver Disease- Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (2024-2034)
14.6.2 Non-alcoholic Fatty Liver Disease- Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (2024-2034)
14.6.3 Non-alcoholic Fatty Liver Disease- Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Non-alcoholic Fatty Liver Disease- Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (2024-2034)
14.7.2 Non-alcoholic Fatty Liver Disease- Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (2024-2034)
14.7.3 Non-alcoholic Fatty Liver Disease- Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Non-alcoholic Fatty Liver Disease- Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (2024-2034)
14.8.2 Non-alcoholic Fatty Liver Disease- Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (2024-2034)
14.8.3 Non-alcoholic Fatty Liver Disease- Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Non-alcoholic Fatty Liver Disease- Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (2024-2034)
14.9.2 Non-alcoholic Fatty Liver Disease- Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (2024-2034)
14.9.3 Non-alcoholic Fatty Liver Disease- Access and Reimbursement Overview
15 NON-ALCOHOLIC FATTY LIVER DISEASE- RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
16 NON-ALCOHOLIC FATTY LIVER DISEASE MARKET - SWOT ANALYSIS
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 APPENDIX
